Kirurgi, inflammatorisk tarmsykdom og biologisk behandling

Tidsskrift for den Norske Laegeforening

Volumn 129, Issue 22, 2009, Pages 2389-2390

  Oresland T ^a   Moum, B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; PREDNISOLONE;

COLON RESECTION; CROHN DISEASE; HUMAN; LETTER; RISK FACTOR; SURGICAL INFECTION; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREDNISOLONE; RISK FACTORS; SURGICAL WOUND INFECTION;

EID: 77951661004     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.09.1231     Document Type: Letter

References (4)

1. Mor IJ, Vogel JD, da Luz Moreira A et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008; 51: 1202-7; discussion 1207-10.
2. Bordeianou L. In flux on infliximab: conflicting studies on surgical outcomes. Inflamm Bowel Dis 2009; 15: 1605-6.
3. Selvasekar CR, Cima RR, Larson DW et al. Effect of infliximab onshort-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007; 204: 956-62; discussion 962-3.
4. Aberra FN, Lewis JD, Hass D et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125: 320-7.